Showing 2481-2490 of 3858 results for "".
A Busy Time in the Field
https://practicaldermatology.com/issues/januaryfebruary-2026/a-busy-time-in-the-field/54452/GLP-1RAs and the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1ras-and-the-dermatologist/48885/We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation.Can Prescription Hyperhidrosis Treatments Help Mitigate Symptoms?
https://practicaldermatology.com/topics/rare-disease/can-prescription-hyperhidrosis-treatments-help-mitigate-symptoms/39997/Remaking Ourselves: Aesthetic Medicine That Is Regenerative
https://practicaldermatology.com/issues/october-2025/remaking-ourselves-aesthetic-medicine-that-is-regenerative/39752/Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuFrom Training to Transformation: How Leaders Get the Most Out of Educating Their Team
https://practicaldermatology.com/issues/september-2025/from-training-to-transformation-how-leaders-get-the-most-out-of-educating-their-team/37640/Imagine investing thousands of dollars in staff time and tuition for the latest aesthetic techniques or business courses—sending employees to conferences or bringing in an expert for in-office training—only to watch those skills fade, or be underused or forgotten.Dr. DiAnne Davis on Mentorship, Lasers, Skin of Color, and More
https://practicaldermatology.com/issues/september-2025/dr-dianne-davis-on-mentorship-lasers-skin-of-color-and-more/37643/In a recent YoungMD Connect virtual mentorship session, DiAnne Davis, MD, FAAD, a dermatologist based in Dallas, discussed her journey from patient to dermatologist, the influence of mentorship, and her commitment to advancing safe, effective cosmetic procedures for patients with skin of color.